Subscribe or Manage Preferences

Lupus

By Wayne Kuznar Although biomarker progress is easily discernible in cardiology and oncology, researchers are only at the beginning of the long, winding road of biomarker discovery in lupus, said Mary K. Crow, MD, Physician-in-Chief, and Chair, Division of Rheumatology, and Director of the Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York City, at the 2012 meeting of the American College of Rheumatology.
By Mary Mosley New recommendations for the management of lupus nephritis (LN) call for a renal biopsy at the earliest sign of kidney dysfunction to guide the use of immunosuppressive treatment in patients with systemic lupus erythematosus (SLE). The goal for treatment is a complete renal response, defined as proteinuria <0.5 g per 24 hours, with normal or near-normal renal function.
By David Hawk Berlin, Germany—A small study presented during a press conference at the 2012 European League Against Rheu­ma­­tism Congress sparked a great deal of interest among rheumatology re­searchers when it was reported that use of the cancer drug bor­tezomib showed a dramatic reduction in symptom scores in patients with systemic lupus erythematosus (SLE) who are refractory to the current standard of care.
For patients with lupus nephritis who have responded to induction therapy, mycophenolate mofetil (CellCept) is superior to azathioprine (Azasan) in maintaining a renal response to treatment and in preventing relapse, according to a recent study...
By Sy Schlager, MD, PhD

Belimumab (Benlysta) has recently been approved in the United States for the treatment of systemic lupus erythematosus (SLE), with a specific indication for use in adult patients with active, autoantibody-positive disease who are currently receiving standard therapies. However, the optimal use of this agent in SLE has not been well defined.

Page 5 of 5
Results 41 - 45 of 45
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology